12th Aug 2015 08:15
LONDON (Alliance News) - Oxford Pharmascience Group PLC said Wednesday that preliminary pharmacokinetic data shows its OXP001(2) ibuprofen tablet met its optimisation objectives for immediate release and complete drug absorption.
OXP001(2) is a 400 milligram chewable, taste masked oral formulation of ibuprofen. The study compared the drug against ibuprofen tablet Brufen in ten subjects.
It has now begun dosing in the second phase of the study, which will look to prove the reduced gastrointestinal irritation of OXP001(2).
"We are confident the product is achieving release properties in line with the objective of delivering a reduction in GI irritation. Demonstrating that OXP001(2) achieves a significant reduction in GI erosions compared to Brufen in this new formulation will validate OXPzero Ibuprofen as a disruptive compound in the major USD4 billion ibuprofen market," said Chief Executive Officer Marcelo Bravo in a statement.
Shares in Oxford Pharmascience were up 4.6% at 8.50 pence Wednesday morning.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright 2015 Alliance News Limited. All Rights Reserved.
Related Shares:
Oxford Pharmascience Group